Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Cellectis S.A.. (3/7/16). "Press Release: Cellectis Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7–9, 2016". New York, NY.

Organisations Organisation Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
  Organisation 2 Cowen & Company LLC
  Group Cowen (Group)
Products Product Cowen & Co. Annual Health Care Conference 2016 Boston
  Product 2 TALEN (Transcription Activator-Like Effector Nuclease)
Index term Index term Cellectis–Cowen: investor conference, 201603 supply service Cellectis presents at Cowen & Co Annual Health Care Conference 2016
Persons Person Moore, Jennifer (Cellectis 201511 VP Communications)
  Person 2 Harnest, Simon (Cellectis 201505 VP Finance + Investor Relations before Trout Group)

Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that it will be presenting at the Cowen and Company 36th Annual Health Care Conference.

The Cellectis presentation will take place on Wednesday, March 9, 2016, from 09:20-09:50 AM US Eastern Time in the Provincetown room, 4th Floor, followed by a breakout session from 10:00-10:30 AM US Eastern Time in the Nantucket room, 4th Floor, at the The Boston Marriott Copley Place Hotel, 110 Huntington Ave, Boston, MA.

A live webcast will be available at

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-sciencefocused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website:

Talking about gene editing? We do it.
TALEN® is a registered trademark owned by the Cellectis Group.

For further information, please contact:

Jennifer Moore, VP Communications
Phone: 917-580-1088
Simon Harnest, VP Finance and Investor Relations
Phone: 646-385-9008

Caitlin Kasunich
KCSA Strategic Communications
Phone: 212-896-1241


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

Record changed: 2017-07-02


Picture [LSUK] – The Business Web Portal 600x80px

More documents for Cellectis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px

» top